Esa Kähkönen

721 total citations
17 papers, 531 citations indexed

About

Esa Kähkönen is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Oncology. According to data from OpenAlex, Esa Kähkönen has authored 17 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 5 papers in Rheumatology and 4 papers in Oncology. Recurrent topics in Esa Kähkönen's work include Prostate Cancer Diagnosis and Treatment (11 papers), Prostate Cancer Treatment and Research (9 papers) and Urologic and reproductive health conditions (5 papers). Esa Kähkönen is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (11 papers), Prostate Cancer Treatment and Research (9 papers) and Urologic and reproductive health conditions (5 papers). Esa Kähkönen collaborates with scholars based in Finland, United States and Austria. Esa Kähkönen's co-authors include Ivan Jambor, Heikki Minn, Pekka Taimen, Hannu J. Aronen, Peter J. Boström, Harri Merisaari, Jukka Kemppainen, Anne Roivainen, Sandra Borkowski and Tuula Tolvanen and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Biochemistry and Scientific Reports.

In The Last Decade

Esa Kähkönen

16 papers receiving 521 citations

Peers

Countries citing papers authored by Esa Kähkönen

Since Specialization

Citations

This map shows the geographic impact of Esa Kähkönen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esa Kähkönen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esa Kähkönen more than expected).

Fields of papers citing papers by Esa Kähkönen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esa Kähkönen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esa Kähkönen. The network helps show where Esa Kähkönen may publish in the future.

Co-authorship network of co-authors of Esa Kähkönen

This figure shows the co-authorship network connecting the top 25 collaborators of Esa Kähkönen. A scholar is included among the top collaborators of Esa Kähkönen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esa Kähkönen. Esa Kähkönen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study 2022 ·European Radiology ·Mohsen Beheshti, Pekka Taimen, Jukka Kemppainen, Ivan Jambor, André Müller, Wolfgang Loidl, Esa Kähkönen, Meeri Käkelä, Mathias Berndt, Andrew Stephens, Heikki Minn, Werner Langsteger	19
2	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study 2020 ·World Journal of Urology ·Ugo Giovanni Falagario, Ivan Jambor, Pekka Taimen, Kari T. Syvänen, Esa Kähkönen, Harri Merisaari, Ileana Montoya Perez, Juha Knaapila, (unknown), (unknown), Ashutosh Tewari, Hannu J. Aronen, Giuseppe Carrieri, Peter J. Boström, Otto Ettala	15
3	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI 2020 ·Scientific Reports ·Parisa Movahedi, Harri Merisaari, Ileana Montoya Perez, Pekka Taimen, Jukka Kemppainen, Anna Kuisma, Olli Eskola, Jarmo Teuho, Jani Saunavaara, M. Pesola, Esa Kähkönen, Otto Ettala, Timo Liimatainen, Tapio Pahikkala, Peter J. Boström, Hannu J. Aronen, Heikki Minn, Ivan Jambor	4
4	IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole‐mount prostatectomy sections and implications for focal therapy 2019 ·Journal of Magnetic Resonance Imaging ·Harri Merisaari, Ivan Jambor, Otto Ettala, Peter J. Boström, Ileana Montoya Perez, (unknown), Aida Kiviniemi, Kari T. Syvänen, Esa Kähkönen, Lauri Eklund, Tapio Pahikkala, Paula Vainio, Jani Saunavaara, Hannu J. Aronen, Pekka Taimen	14
5	Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study 2018 ·British Journal of Urology ·Juha Knaapila, (unknown), Antti Hakanen, Kari T. Syvänen, Otto Ettala, Esa Kähkönen, Tarja Lamminen, (unknown), Ivan Jambor, Antti Rannikko, Jarno Riikonen, Eveliina Munukka, Erkki Eerola, Marianne Gunell, Peter J. Boström	13
6	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort 2017 ·European Urology Focus ·Juha Knaapila, Marianne Gunell, Kari T. Syvänen, Otto Ettala, Esa Kähkönen, Tarja Lamminen, (unknown), Ivan Jambor, Antti Rannikko, Jarno Riikonen, Eveliina Munukka, Erkki Eerola, Antti Hakanen, Peter J. Boström	11
7	Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial) 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·Ivan Jambor, Anna Kuisma, Esa Kähkönen, Jukka Kemppainen, Harri Merisaari, Olli Eskola, Jarmo Teuho, Ileana Montoya Perez, M. Pesola, Hannu J. Aronen, Peter J. Boström, Pekka Taimen, Heikki Minn	56
8	Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial) 2017 ·Journal of Magnetic Resonance Imaging ·Ivan Jambor, Peter J. Boström, Pekka Taimen, Kari T. Syvänen, Esa Kähkönen, Markku Kallajoki, Ileana Montoya Perez, Tommi Kauko, Jaakko Matomäki, Otto Ettala, Harri Merisaari, Aida Kiviniemi, Peter B. Dean, Hannu J. Aronen	67
9	Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care 2016 ·Scandinavian Journal of Urology ·Jarno Riikonen, Antti Kaipia, Anssi Pétas, Antero Horte, Juha Koskimäki, Esa Kähkönen, Peter J. Boström, Ilkka Paananen, (unknown), Henrikki Santti, Mika Matikainen, Antti Rannikko	16
10	Stratification of aggressive prostate cancer from indolent disease—Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue 2016 ·Urologic Oncology Seminars and Original Investigations ·(unknown), (unknown), (unknown), Ileana Montoya Perez, Ivan Jambor, Hannu J. Aronen, Esa Kähkönen, Otto Ettala, Kari T. Syvänen, Matthias Nees, Markku Kallajoki, Pekka Taimen, Peter J. Boström, Kim Pettersson	10
11	Detection of prostate cancer with the [⁶⁸Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy. 2016 ·Journal of Clinical Oncology ·Andrew Stephens, Wolfgang Loidl, Mohsen Beheshti, Ivan Jambor, Jukka Kemppainen, Peter J. Boström, Esa Kähkönen, Mathias Berndt, André Mueller, Heikki Minn, Werner Langsteger	4
12	Local delivery of a selective androgen receptor modulator failed as an anabolic agent in a rat bone marrow ablation model. 2015 ·PubMed ·Hannu T. Aro, Julia Kulkova, Niko Moritz, Esa Kähkönen, (unknown)	4
13	Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy 2014 ·Journal of Magnetic Resonance Imaging ·Ivan Jambor, Esa Kähkönen, Pekka Taimen, Harri Merisaari, Jani Saunavaara, Kalle Alanen, (unknown), Heikki Minn, (unknown), Hannu J. Aronen	42
14	Lanthanide chelate complementation and hydrolysis enhanced luminescent chelate in real-time reverse transcription polymerase chain reaction assays for KLK3 transcripts 2013 ·Analytical Biochemistry ·(unknown), (unknown), (unknown), Ulla Karhunen, Tero Soukka, Esa Kähkönen, Pekka Taimen, Kalle Alanen, Kim Pettersson	2
15	In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 2013 ·Clinical Cancer Research ·Esa Kähkönen, Ivan Jambor, Jukka Kemppainen, Kaisa Lehtiö, Tove J. Grönroos, Anna Kuisma, Pauliina Luoto, (unknown), Tuula Tolvanen, Kalle Alanen, (unknown), Markku Kallajoki, Anne Roivainen, Niklaus Schäfer, Roger Schibli, (unknown), Anass Johayem, Ray Valencia, Sandra Borkowski, Heikki Minn	162
16	Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of ⁶⁸Ga Bombesin Antagonist BAY 86-7548 in Healthy Men 2013 ·Journal of Nuclear Medicine ·Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, B. Hofmann, Ivan Jambor, Kaisa Lehtiö, (unknown), Antje Rottmann, (unknown), (unknown), Sami Suilamo, Tuula Tolvanen, Ray Valencia, Heikki Minn	92
17	Virtsarakon katetrointi ja kystostooman laitto 2009 ·Matti Laato, Esa Kähkönen, Antti Rannikko, Peter J. Boström	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact